Sandra Kear

A new study has uncovered notable disparities in uptake of adjuvant breast cancer therapies in the Appalachian region of the United States, suggesting targeted intervention strategies may help to improve outcomes for this population of women.

One of the first studies to prospectively examine women's breast surgery preferences has revealed that newly diagnosed women with breast cancer who decide to undergo contralateral prophylactic mastectomy (CPM) aren't relying on evidence-based information, highlighting the need for interdisciplinary patient education and communication.

Adjuvant exemestane reduced the relative risk of developing subsequent invasive cancer in hormone-receptor–positive (HR+) premenopausal women by 28% compared with tamoxifen when both agents were combined with ovarian function suppression (OFS)